key: cord-0956207-eisv1ayi
authors: Freedberg, Daniel E.; Wang, Timothy C.; Abrams, Julian A.
title: Famotidine and COVID-19
date: 2020-12-30
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.12.044
sha: 253c28df74f8179c9cf1e986ff50665ea61f77e3
doc_id: 956207
cord_uid: eisv1ayi

nan

Yeramaneni et al. report results from a retrospective study testing associations between use of famotidine and outcomes among patients with COVID-19. 1 Like our recent retrospective study on the same topic, they classified use of famotidine based on exposure within 24 hours following hospital admission and followed patients with COVID-19 for death for up to 30 days. 2 Interestingly, while our study found a nearly 2-fold protective association between use of famotidine and death or intubation (aHR 0.42, 95% CI 0.21-0.85), Yeramaneni found no association between famotidine and death (aOR 1.59, 95% CI 0.94-2.71). Why might the two studies, so similar in design, have such different results?

First, it is possible that differences related to institutional patterns of use of famotidine underlie the discrepancy in study findings. For example, if famotidine was often used for stress ulcer prophylaxis in critically patients at Yeramaneni's institution, then patients who received famotidine may have been sicker at baseline than those who did not. 16% of patients used famotidine in Yeramaneni's study compared to 5% in ours, implying a fundamental difference related to institutional patterns of use. Prior to matching, patients who used famotidine at Yeramaneni's institution were sicker in almost every way (higher oxygen requirements, more comorbidities, etc.) whereas this was not true in our cohort. After matching, differences within Yeramaneni's cohort are likely to persist in the unmatched categories. Given the significant baseline differences between those who used famotidine and those who did not, these residual cohort, excluding those who used famotidine in the hospital, would be interesting. One possibility is that early, but not late use of famotidine may be beneficial in COVID-19. 3 Examining the totality of evidence, what do we have? Our study and other retrospective studies of famotidine suggest there may be an association between use of famotidine and improved outcomes among hospitalized patients with COVID-19; 4, 5 this was also suggested by a case series of famotidine with quantitative symptom tracking in non-hospitalized patients. 3 The data from Yeramaneni et al. and other retrospective studies show no association. 6, 7 We agree with Yeramaneni that famotidine should only be used as COVID-19 therapy in the context of a clinical trial. Such trials are ongoing, and the results of these trials will be the crucial next step in answering the question of whether there is a role for famotidine in COVID-19. 8, 9 Daniel E. Freedberg 

Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized COVID-19 Patients from a Large Healthcare System

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients

Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Multi-site Adaptive Trials for COVID-19

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial